(Reuters) – Biotechnology company Septerna said on Monday it is aiming to raise up to $186 million in its initial public offering in the United States.
The company is looking to sell 10.9 million shares priced between $15 and $17 each, it said.
Septerna will join a growing list of biotech firms that have gone public recently, driven by lower interest rates that encourage more startups to list their shares.
J.P. Morgan, TD Cowen, Cantor and Wells Fargo Securities are the underwriters for the IPO.
(Reporting by Niket Nishant in Bengaluru; Editing by Shilpi Majumdar)
Comments